Business Context and Reporting Period
This Form 8-K filing by Capricor Therapeutics, Inc. (CAPR) reports a corporate governance event occurring on May 14, 2024, with the amendment effective May 15, 2024. The Company is a Delaware corporation headquartered in San Diego, California, with common stock trading on the Nasdaq Capital Market.
Financial Metrics
This filing is a current report regarding a change in the Company's Articles of Incorporation. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. No financial metrics are reported in this document.
Material Changes
- Authorized Share Increase: Stockholders approved an amendment to the Certificate of Incorporation to increase the number of authorized shares of common stock from 50,000,000 to 100,000,000.
- Regulatory Filing: The Company filed the Certificate of Amendment with the Secretary of State of Delaware on May 15, 2024, making the change effective immediately.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is strictly procedural, summarizing the shareholder approval and subsequent filing of the amendment to the Certificate of Incorporation.
Key Facts for Investor Verification
- Verify the effective date of the share authorization increase (May 15, 2024).
- Confirm the new total authorized common shares (100,000,000) versus the prior limit (50,000,000).
- Review the attached Exhibit 3.1 (Certificate of Amendment) for the complete legal text of the amendment.
- Note that this filing does not impact the Company's outstanding share count or capitalization directly, but increases the capacity for future issuances.